Open Access

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

  • Rachelle S Doody1,
  • Rema Raman2, 3,
  • Reisa A Sperling4,
  • Eric Seimers5,
  • Gopalan Sethuraman5,
  • Richard Mohs5,
  • Martin Farlow6,
  • Takeshi Iwatsubo7,
  • Bruno Vellas8,
  • Xiaoying Sun9,
  • Karin Ernstrom9,
  • Ronald G Thomas3, 10,
  • Paul S Aisen3Email author and
  • for the Alzheimer’s Disease Cooperative Study
Alzheimer's Research & Therapy20157:36

DOI: 10.1186/s13195-015-0121-6

Received: 15 August 2014

Accepted: 16 March 2015

Published: 10 June 2015

Abstract

Introduction

The negative efficacy study examining the γ-secretase inhibitor semagacestat in mild to moderate Alzheimer’s disease (AD) included a number of biomarkers of the disease as well as safety outcomes. We analyzed these data to explore relationships between drug exposure and pharmacodynamic effects and to examine the correlations among outcome measures.

Methods

The study was a multicenter, randomized, placebo-controlled trial of two dose regimens of semagacestat and a placebo administered for 18 months to individuals with mild to moderate AD. Changes in measures of central and peripheral drug activity were compared between the three treatment groups using one-way analysis of variance. The relationship between changes in each of the outcome measures and measures of drug exposure and peripheral pharmacodynamic effect were assessed using Spearman’s correlation coefficient.

Results

Assignment to the active treatment arms was associated with reduction in plasma amyloid-β (Aβ) peptides, increase in ventricular volume, decrease in cerebrospinal fluid phosphorylated tau (p-tau) and several other laboratory measures and adverse event categories. Within the active arms, exposure to drug, as indicated by area under the concentration curve (AUC) of blood concentration, was associated with reduction in plasma Aβ peptides and a subset of laboratory changes and adverse event rates. Ventricular volume increase, right hippocampal volume loss and gastrointestinal symptoms were related to change in plasma Aβ peptide but not AUC, supporting a link to inhibition of γ-secretase cleavage of the amyloid precursor protein. Cognitive decline correlated with ventricular expansion and reduction in p-tau.

Conclusion

These findings may inform future studies of drugs targeting secretases involved in Aβ generation.

Trial registration

ClinicalTrials.gov Identifier: NCT00594568. Registered 11 January 2008.

Introduction

One leading theory of the pathogenesis of Alzheimer’s disease (AD) considers the sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretases to release amyloidogenic peptides to be the initiating and driving event in this neurodegenerative condition [1]. Inhibition of secretases has therefore been a major strategy in efforts to develop disease-modifying treatments for AD [2]. The strategy of γ-secretase inhibition to slow disease progression is further supported by the finding that the most common mutations that cause familial autosomal dominant AD involve presenilin, a γ-secretase component [3].

The first large-scale study of a γ-secretase modulating drug, flurbiprofen, was ineffective [4]. This failure has been attributed to insufficient pharmacodynamic effects in the brain. More recently, novel γ-secretase inhibitors have demonstrated target engagement, as indicated by reduction in cerebrospinal fluid (CSF) levels of amyloid peptides [5,6]. A major concern about this drug class has been adverse effects related to impact on non-target substrates [6-8]. In particular, Notch cleavage by γ-secretase may be inhibited by such drugs [9], with adverse effects on the gastrointestinal, immune and cutaneous systems.

Semagacestat is generally referred to as a γ-secretase inhibitor, but we note that it increases levels of amyloid-β peptide 42 (Aβ42) in the blood at low concentrations, suggesting that it may exert its activity at an allosteric site rather than the active site of the enzyme. It does not increase generation of shorter peptides (such as Aβ38), which is a characteristic of drugs referred to as γ-secretase modulators.

Semagacestat was the first γ-secretase inhibitor to reach Phase III testing in AD. The development of this drug was spurred by strong evidence for a central pharmacodynamic effect in a study in which researchers used stable isotope labeling with CSF sampling to determine the kinetics of amyloid peptide production [7]. The phase III trial, the primary results of which are reported elsewhere [10], was terminated before planned completion because of evidence of cognitive and other adverse effects in the active treatment group. Data derived from the trial afford an opportunity to evaluate the peripheral laboratory and clinical effects and the central effects of γ-secretase inhibition in AD. This experience may inform other ongoing efforts to target this enzyme complex.

Methods

Patients, drug dosing and blinding

The present study was approved by the institutional review boards at each participating site (see Additional file 1). Subjects aged 55 years or older with mild to moderate AD (Mini Mental State Examination (MMSE) [11] score between 16 and 26 at screening) who met National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association criteria [12] and were in good general health and free of depression (Geriatric Depression Scale score ≤6) [13]) were randomized to escalate to 100 mg once daily or 140 mg once daily of semagacestat or placebo over 76 weeks using a triple dummy to blind dosage groups. Doses were titrated as follows: 60 mg for 2 weeks, then 100 mg; or 60 mg for 2 weeks, 100 mg for 2 weeks, then 140 mg. At baseline, subjects could be untreated or treated with background cholinesterase inhibitors with or without memantine, as long as they had been on the drug for at least 4 weeks and the doses of antidementia drugs were stable for at least 2 months. All subjects signed informed consent forms prior to participating in study procedures.

Cognitive measures

Patients were assessed with the 11-item version of the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAScog11) [14] at baseline and weeks 12, 28, 40, 52, 64, 76 and 88 or at early termination and with the MMSE at screening, baseline and weeks 52, 76 and 88 or early termination.

Biological markers and imaging outcome measures

Patients were genotyped for apolipoprotein E polymorphisms. Special lymphocyte hematology was done at baseline and weeks 12, 28, 40, 52, 64, 76 and 88 or early termination. Plasma Aβ was assessed at baseline and weeks 6, 12 and 52 or early termination. Optional CSF analysis for Aβ peptides and tau and phosphorylated tau (p-tau) proteins was conducted in willing subjects. Volumetric magnetic resonance imaging (vMRI), amyloid imaging with florbetapir (AV45) fludeoxyglucose positron emission tomography (FDG-PET), and CSF analyses were performed at baseline and week 76 or early termination. Additional details regarding methods are provided in the Appendix to the article describing the primary results of the phase III trial [10].

Pharmacokinetic measures

Pharmacokinetic (PK) samples were collected at week 6, 12 and 52. Population PK analysis was performed using a nonlinear mixed-effects model. The model estimated individual clearance values for each subject using all concentrations collected at each visit, taking into account time from dose, the dose level administered, and estimated residual error that resulted from assay error, inaccurate sample time information or inaccurate dosing information. The clearance estimate for each individual was used to calculate area under the concentration curve (AUC) using standard equations. A similar process was undertaken to generate maximum concentration (Cmax) using standard equations to calculate Cmax and individual estimates for various PK parameters.

Alzheimer’s Disease Cooperative Study Data Analysis and Publication Committee

The Data Analysis and Publication Committee (DAPC) was funded by a grant from Eli Lilly to the University of California at San Diego as fiduciary for the Alzheimer’s Disease Cooperative Study (ADCS) after the semagacestat phase III studies were halted, but before the datasets were transferred to the ADCS. The timing of the contract was designed to remove any concern that payment for the work of data analysis and publication would be dependent upon the outcome. The DAPC developed a document of governance that specifies voting members of the committee, as well as non-voting members, who include a limited number of Eli Lilly employees who are familiar with the study and the data and one non-voting representative each of the Data Safety Monitoring Committee and the National Institute on Aging. The DAPC also developed a data dissemination plan and kept the ADCS Steering Committee apprised of its progress by formal reports at each Steering Committee meeting. The final publication was developed by the committee and approved by the voting members of the DAPC committee and the ADCS steering committee, and non-voting DAPC members gave feedback but did not have veto power.

Statistical analysis

Changes in outcome measures reflecting central and peripheral activity of semagacestat were compared between the three treatment groups using one-way analysis of variance. Analyses included all randomized subjects with available data. Annualized change from baseline in cognitive, CSF and three imaging outcomes (vMRI, FDG-PET and AV45) were calculated based on the last available observation in the initial treatment period. The outcome for plasma Aβ used percentage change from baseline to 6 hours postdose at week 52. Laboratory measures included change from baseline in uric acid, albumin and eosinophils at week 76. Specific adverse events, including gastrointestinal, skin disorder, skin cancer and infection incidence, were compared between the three treatment groups using the Fisher-Freeman-Halton exact test. The relationship between change in each of the outcome measures (cognitive tests, plasma Aβ, CSF assays, vMRI, FDG-PET and rates of specific adverse events) and measures of drug exposure (AUC in the active treatment group) and peripheral pharmacodynamic effects (changes in plasma Aβ) were assessed using Spearman’s correlation coefficient [15]. R version 2.14.1 statistical software [16] was used for all statistical analyses. We did not employ corrections for multiple comparisons in this exploratory analysis.

Results

Outcomes by treatment group

Summary statistics of key outcomes are shown in Table 1 for the three arms of the trial. Treatment assignment was associated with ventricular volume (greater ventricular expansion in high-dose arm), CSF p-tau (increase in placebo arm, reduction in treatment arms), plasma Aβ peptides (dose-related reduction in active arms) and several laboratory measures and adverse event categories (Table 1). The relationship between arm assignment and change in plasma Aβ peptides is shown in Figure 1. Levels of both species of amyloid peptide had declined in both active treatment arms by week 6, and the reductions were sustained until week 52 (the final analysis time point for plasma amyloid peptides).
Table 1

Outcomes by treatment arms a

 

Placebo

LY 100 mg

LY 140 mg

P -value

Annualized change in ADASCog11

4.75 ± 21.92 (n = 485)

6.57 ± 25.57 (n = 482)

5.48 ± 21.92 (n = 495)

0.408

Annualized change in MMSE

−2.19 ± 3.65 (n = 396)

−2.56 ± 3.65 (n = 324)

−2.92 ± 3.65 (n = 303)

0.159

Annualized change in FDG-PET SUVR

−0.06 ± 0.07 (n = 40)

−0.13 ± 0.21 (n = 42)

−0.1 ± 0.08 (n = 33)

0.109

Annualized change in AV45 SUVR

0.05 ± 0.11 (n = 18)

0.02 ± 0.24 (n = 23)

0.07 ± 0.23 (n = 18)

0.794

Annualized change in ventricular volume

4.07 ± 3.52 (n = 80)

4.19 ± 3.92 (n = 74)

5.68 ± 4.68 (n = 67)

0.033

Annualized change in right hippocampal volume

−86.28 ± 73.86 (n = 74)

−91.08 ± 102.1 (n = 68)

−90.98 ± 71.1 (n = 64)

0.926

Annualized change in left hippocampal volume

−68.85 ± 59.01 (n = 74)

−70.4 ± 90.81 (n = 68)

−91.0 ± 101.2 (n = 64)

0.244

Annualized change in CSF Aβ40

87.66 ± 847 (n = 10)

−10.96 ± 1151 (n = 19)

−599 ± 1786 (n = 18)

0.328

Annualized change in CSF Aβ42

10.96 ± 87.66 (n = 10)

−40.18 ± 109.6 (n = 19)

−36.5 ± 182.7 (n = 18)

0.619

Annualized change in p-tau

10.96 ± 7.31 (n = 10)

−7.31 ± 14.61 (n = 19)

−3.65 ± 10.96 (n = 18)

0.009

Annualized change in total tau

94.97 ± 116.9 (n = 10)

−43.83 ± 219.2 (n = 17)

40.18 ± 127.8 (n = 18)

0.101

Percentage change in plasma Aβ40 at week 52

4.77 ± 26.67 (n = 307)

−37.54 ± 109.3 (n = 264)

−47.76 ± 32.06 (n = 243)

<0.001

Percentage change in plasma Aβ42 at week 52

3.82 ± 20.75 (n = 309)

−5.4 ± 53.1 (n = 265)

−18.14 ± 33.0 (n = 245)

<0.001

Change in uric acid at week 76

0.18 ± 0.83 (n = 210)

−0.96 ± 1.08 (n = 179)

−0.88 ± 1.22 (n = 147)

<0.001

Change in albumin at week 76

0 ± 0.25 (n = 210)

−0.09 ± 0.31 (n = 179)

−0.09 ± 0.3 (n = 147)

0.002

Change in eosinophils at week 76

−0.001 ± 0.09 (n = 207)

0.05 ± 0.17 (n = 179)

0.06 ± 0.14 (n = 143)

<0.001

Gastrointestinal symptoms

153 (31.5%)

169 (34.9%)

193 (38.8%)

0.057

Skin disorder incidence

105 (21.6%)

220 (45.4%)

269 (54%)

<0.001

Skin cancer incidence

8 (1.7%)

51 (10.5%)

56 (11.2%)

<0.001

Infection incidence

156 (32.1%)

188 (38.8%)

220 (44.2%)

<0.001

AUC

 

5,316 ± 1,525 (n = 480)

7,235 ± 2233 (n = 494)

<0.001

Cmax

 

1,105 ± 260 (n = 480)

1,508 ± 384 (n = 494)

<0.001

aAβ40, Amyloid-β peptide 40; Aβ42, Amyloid-β peptide 42; ADAScog11, Alzheimer’s Disease Assessment Scale–Cognitive Subscale, 11-item version; AUC, Area under the curve; AV45, Florbetapir; Cmax, Maximum concentration; CSF, Cerebrospinal fluid; FDG-PET, Fludeoxyglucose positron emission tomography; LY, Semagacestat; MMSE, Mini Mental State Examination; p-tau, Phosphorylated tau; SUVR, Standard uptake value ratio.

Figure 1

Change in plasma amyloid-β peptide levels. Abeta, Amyloid-β; LY100mg, Semagacestat 100 mg; LY140mg, Semagacestat 140 mg.

As expected, the mean AUC and Cmax increased with increasing dose, although there was overlap between the dose groups.

Correlational analyses

Among adverse events, correlational analyses suggested that gastrointestinal symptoms, rash and skin cancer may be related to each other, while uric acid reduction, albumin reduction and infection formed a cluster (Table 2). Among markers of central nervous system effects, decline in cognition measured either by increase in ADAScog11 score or decrease in MMSE score correlated with each other and with ventricular expansion (Table 3). Consistent with the overall groupwise effects, there was an unexpected correlation between reduction in CSF p-tau and cognitive decline.
Table 2

Correlations between peripheral biomarkers a

 

AUC

Plasma Aβ40

Uric acid

Albumin

EOS

GI

Skin

Skin cancer

Infection

AUC

1; 0

−0.36; 0.001

−0.15; 0.007

−0.14; 0.01

0.18; 0.001

0.02; 0.65

−0.02; 0.63

−0.01; 0.81

0.14; 0.001

Plasma Aβ40

 

1; 0

−0.01; 0.86

0.131; 0.03

−0.19; 0.002

−0.10; 0.03

−0.08; 0.06

−0.08; 0.09

−0.07; 0.11

Uric acid

  

1; 0

0.08; 0.13

−0.23; 0.001

0.03; 0.60

−0.12; 0.04

−0.08; 0.13

−0.11; 0.04

Albumin

   

1; 0

−0.22; 0.001

0.05; 0.42

0.02; 0.72

0.02; 0.68

−0.15; 0.006

EOS

    

1; 0

−0.01; 0.85

0.04; 0.50

0.11; 0.06

0.08; 0.17

GI

     

1; 0

0.11; 0.001

0.05; 0.16

0.17; 0.001

Skin

      

1; 0

0.14; 0.001

0.13; 0.001

Skin cancer

       

1; 0

0.123; 0.001

Infection

        

1; 0

aAβ40, Amyloid-β peptide 40; AUC, Area under the concentration curve; EOS, Eosinophils; GI, Gastrointestinal. Data are Spearman’s correlation coefficients and P-values (r; P).

Table 3

Correlations between changes in central biomarkers a

 

Ventricular volume

CSF p-tau

CSF Aβ42

ADAScog11

MMSE

FDG-PET SUVR

−0.43; 0.007

−0.14; 0.79

0.37; 0.47

−0.11; 0.36

0.23; 08

Ventricular volume

1; 0

−0.14; 0.62

−0.12; 0.67

0.46; 0.001

−0.54; 0.001

CSF p-tau

 

1; 0

0.37; 0.49

−0.40; 0.02

0.33; 0.05

CSF Aβ42

  

1; 0

−0.12; 0.48

0.31; 0.08

ADAScog11

   

1; 0

−0.58; 0.001

aAβ42, Amyloid-β peptide 42; ADAScog11, Alzheimer’s Disease Assessment Scale–Cognitive Subscale, 11-item version; CSF, Cerebrospinal fluid; FDG-PET, Fludeoxyglucose positron emission tomography; MMSE, Mini Mental State Examination; p-tau, Phosphorylated tau; SUVR, Standard uptake value ratio. Data are Spearman’s correlation coefficients and P-values (r; P).

To determine whether clinical and laboratory effects were more closely associated with drug exposure or with the target pharmacodynamic effects (inhibition of γ-secretase cleavage of the APP to release amyloidogenic peptides), we examined the correlation between measures and semagacestat AUC and change in plasma Aβ40, respectively (Table 4). We used Aβ40 rather than Aβ42 because the latter values were confounded in some cases by measurement below the level of detection.
Table 4

Correlations of change in selected outcome measures with drug exposure and reduction in plasma amyloid-β peptide 40 in the active arms a

 

Semagacestat AUC

Change in plasma Aβ40

AUC adjusted for Aβ40

Aβ40 adjusted for AUC

 

r

n

P

r

n

P

r

n

P

r

n

P

Change in uric acid at week 76

−0.151

320

0.007

0.011

263

0.857

−0.149

260

0.016

0.071

260

0.255

Change in albumin at week 76

−0.14

320

0.012

−0.131

263

0.033

−0.037

260

0.548

−0.107

260

0.084

Gastrointestinal symptoms

0.015

943

0.654

0.099

507

0.025

−0.004

501

0.933

0.094

501

0.034

Skin disorder incidence

0.016

943

0.627

0.083

507

0.062

−0.048

501

0.279

0.096

501

0.031

Skin cancer incidence

−0.012

943

0.71

0.075

507

0.091

−0.039

501

0.389

0.084

501

0.059

Infection incidence

0.136

943

<0.001

0.072

507

0.101

0.068

501

0.129

0.042

501

0.344

Annualized change in FDG SUVR

0.22

74

0.06

<0.001

48

0.998

0.357

48

0.010

−0.134

48

0.364

Annualized change in ventricular volume

0.003

139

0.97

0.242

91

0.021

−0.109

91

0.302

0.264

91

0.010

Annualized change in right hippocampal volume

−0.064

130

0.472

−0.264

86

0.014

−0.039

86

0.719

−0.222

86

0.038

Annualized change in left hippocampal volume

−0.109

130

0.216

−0.036

86

0.74

−0.167

86

0.123

0.043

86

0.697

Annualized change in AV45 SUVR

0.133

40

0.414

0.316

27

0.109

−0.079

27

0.697

0.324

27

0.093

Annualized change in ADASCog11

−0.012

938

0.707

0.037

505

0.403

−0.080

499

0.074

0.060

499

0.177

Annualized change in MMSE

0.038

618

0.351

−0.019

496

0.678

0.057

490

0.211

−0.037

490

0.414

Annualized change in p-tau

0.02

37

0.909

−0.124

33

0.491

0.101

33

0.578

−0.154

33

0.395

Annualized change in total tau

0.07

35

0.691

0.003

31

0.986

−0.017

31

0.930

0.010

31

0.957

Annualized change in CSF Aβ42

−0.13

37

0.443

0.152

33

0.399

−0.103

33

0.571

0.179

33

0.318

aAβ40, Amyloid-β peptide 40; Aβ42, Amyloid-β peptide 42; ADAScog11, Alzheimer’s Disease Assessment Scale Cognitive Subscale, 11-item version; AUC, Area under the concentration curve; AV45, Florbetapir; CSF, Cerebrospinal fluid; FDG-PET, Fludeoxyglucose positron emission tomography; MMSE, Mini Mental State Examination; p-tau, Phosphorylated tau; SUVR, Standard uptake value ratio.

Uric acid reduction was correlated to drug exposure but not to plasma Aβ change, suggesting a mechanism distinct from inhibition of APP cleavage such as drug-induced Fanconi syndrome. Reduction in serum albumin and increase in eosinophil counts correlated with both AUC and reduction in plasma Aβ. There was a trend relating decrease in FDG PET SUVR to AUC, but no relationship with change in plasma Aβ reducing the likelihood that the proposed pharmacological mechanism of the drug influenced FDG signal. In contrast, gastrointestinal symptoms were related to plasma Aβ change but not to drug exposure, consistent with a shared mechanism related to γ-secretase cleavage of APP. Of note, MRI volumetric change, specifically atrophy as indicated by increase in ventricular volume, was also correlated to change in plasma Aβ. Because drug exposure and change in plasma Aβ40 are strongly correlated, adjusting the correlations of each with the other generally reduces the association of each measure; however, the relationship between change in plasma Aβ40 and ventricular volume and right hippocampal volume were essentially unaffected by adjustment for AUC.

Discussion

Semagacestat reduced plasma levels of Aβ peptides, consistent with γ-secretase inhibition in the periphery. The absence of an effect on CSF Aβ peptide levels was consistent with the findings in the phase II trial [17] and may have been related to the small numbers of lumbar punctures and their timing in relation to dosing [7,17]. Thus, unlike our previous study in which we used the stable isotope labeling kinetic technique [7], the available data from this trial do not confirm adequate target engagement in the central nervous system, clouding interpretation of the results.

The most notable central nervous system effect was an adverse effect on cognition in the high-dose arm, leading to early termination of the trial, and a reduction in change in CSF p-tau in the active arms compared with placebo [10]. The p-tau effect is difficult to interpret. Although it is consistent with a possible beneficial effect on disease pathology, suggesting a link between Aβ peptide production and downstream tau abnormalities, the fact that p-tau decreases have been found in longitudinal studies of AD [18] could also mean that this finding was associated with increased neurodegeneration due to accelerated disease. The worsening of cognition in the face of these findings suggests that a substrate of γ-secretase other than APP may have been responsible for the cognitive effects. However, p-tau increased in the placebo group more than it decreased in the treated group, which may point to some instability in the assay. In contrast, the correlational studies link the drug-related change in plasma Aβ to increased brain atrophy. Whereas such atrophy has been associated with antiamyloid immunotherapy and could be related to reduction in inflammation or other effects of amyloid removal, the present data link atrophy to an adverse effect on cognition consistent with a deleterious pharmacological effect on the disease process. Further, it must be emphasized that these analyses do not establish causality and are confounded by dependence among the various measures.

Similar adverse effects have been reported with another γ-secretase inhibitor, avagacestat [6]. Specifically, gastrointestinal and skin rash findings, non-melanoma skin cancer and worsening cognition at higher doses were observed with that drug, strongly supporting a link to γ-secretase inhibition. The development of semagacestat [19,20] has been discontinued. A number of research groups continue to pursue γ-secretase modulation and β-site APP-cleaving enzyme 1 (or BACE) inhibition as alternative, perhaps safer, routes to reduction of amyloid peptide production.

If the adverse effects are related to off-target substrates, γ-secretase modulators, which do not act at the active site of the enzyme complex and do not interfere with cleavage of non-APP substrates, may not carry these risks. But the correlational analyses seem more consistent with a direct relationship among adverse clinical effects, increase in atrophy, cognitive decline and possibly p-tau reduction.

There were correlations among peripheral and central measures of drug level and activity and adverse effects on cognition, consistent with related mechanisms. However, causality cannot be inferred; each of these effects is related to drug exposure, so correlations among them are expected. Observed drug effects could be related to inhibition of cleavage of substrates other than APP. Semagacestat is a non-specific inhibitor of γ-secretase, and the half-maximal effective concentration (EC50) for inhibition of Notch cleavage has been reported to be similar to that for APP cleavage [21]; other methods have indicated a tenfold stronger inhibition of Notch cleavage [22]. Presumably, the EC50 of semagacestat for other transmembrane proteins that are substrates for γ-secretase may be in the same range. On the basis of the clinical trial results alone, the question could be raised whether a lower dose of semagacestat given twice daily might have been better tolerated; however, toxicology studies using beagle dogs and rats showed that the same total daily dose of semagacestat was tolerated very poorly when divided into twice daily dosing due to findings consistent with Notch-mediated gastroenteropathy (data on file, Eli Lilly & Company). It also remains possible that inhibition of γ-secretase cleavage of APP is related to the adverse effect on cognition observed in the high-dose arm of this trial. Further studies of γ-secretase inhibitors and modulators should include monitoring for adverse systemic and cognitive effects.

Progression of AD is characterized by decline in cognitive performance and atrophy of brain tissue. In the semagacestat trial, high-dose treatment had an adverse effect on cognition [10], and in the present analyses, cognitive decline was related to expansion of ventricular volume. The relationship between reduction in CSF p-tau and worsening cognition among those treated with semagacestat cannot be readily explained with the available data. Treatment effects on cognitive and biomarker measures in AD may not be predicted by the patterns of longitudinal change noted in observational studies. Elucidation of the mechanisms of these discordant effects will require data derived from additional trials of various therapeutic interventions, as well as more longitudinal data on biomarker changes in mild to moderate AD.

Conclusions

Analysis of the relationships among PK/pharmacodynamic measures, biomarkers and laboratory tests in the phase III trial of semagacestat in mild to moderate AD provides some insight into the neurobiological and clinical impact of γ-secretase inhibition. Exposure to drug was associated with reduction in plasma Aβ peptides, as well as a subset of laboratory changes and adverse event rates. Measures of brain atrophy and gastrointestinal symptoms were related to changes in plasma Aβ peptide but not drug concentration, supporting a link to inhibition of γ-secretase cleavage of the APP. Cognitive decline correlated with ventricular expansion and reduction in p-tau. These findings may be useful to future investigators in the design of studies targeting secretases involved in Aβ generation.

Abbreviations

ADAScog11: 

Alzheimer’s Disease Assessment Scale–Cognitive Subscale, 11-item version

Aβ: 

Amyloid-β

AUC: 

Area under the concentration curve

AD: 

Alzheimer’s disease

ADCS: 

Alzheimer’s Disease Cooperative Study

APP: 

Amyloid precursor protein

AV45: 

Florbetapir

Cmax

Maximum concentration

CSF: 

Cerebrospinal fluid

DAPC: 

Data Analysis and Publication Committee

EC50

Half-maximal effective concentration

EOS: 

Eosinophils

FDG-PET: 

Fludeoxyglucose positron emission tomography

GI: 

Gastrointestinal

LY: 

Semagacestat

MMSE: 

Mini Mental State Examination

PK: 

Pharmacokinetic

p-tau: 

Phosphorylated tau

SUVR: 

Standard uptake value ratio

vMRI: 

Volumetric magnetic resonance imaging

Declarations

Acknowledgements

The phase III semagacestat study was funded and conducted by Eli Lilly. The Alzheimer’s Disease Cooperative Study (ADCS) is funded by the National Institute on Aging of the National Institutes of Health. The ADCS Data and Publications Committee was supported by advance funding from Eli Lilly.

Authors’ Affiliations

(1)
Alzheimer’s Disease and Memory Disorders center, Department of Neurology, Baylor College of Medicine
(2)
Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, Department of Neurosciences, University of California San Diego
(3)
Department of Neurosciences, University of California San Diego
(4)
Department of Neurology, Harvard Medical School
(5)
Eli Lilly & Company, Lilly Corporate Center
(6)
Department of Neurology, Indiana University, Indiana Alzheimer Disease Center
(7)
Graduate School of Medicine, University of Tokyo
(8)
Gerontopole UMR INSERM 1027, CHU, University of Toulouse
(9)
Biostatistics Research Center, Department of Family and Preventive Medicine, University of California San Diego
(10)
Alzheimer’s Disease Cooperative Study, Department of Family and Preventive Medicine, Department of Neurosciences, University of California San Diego

References

  1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6. A published erratum appears in. Science. 2002;297:2209.View ArticleGoogle Scholar
  2. Salloway S, Mintzer J, Weiner MF, Cummings JL. Disease-modifying therapies in Alzheimer’s disease. Alzheimers Dement. 2008;4:65–79.View ArticlePubMedGoogle Scholar
  3. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature. 1998;391:387–90.View ArticlePubMedGoogle Scholar
  4. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302:2557–64.View ArticlePubMed CentralPubMedGoogle Scholar
  5. Dockens R, Wang JS, Castaneda L, Sverdlov O, Huang SP, Slemmon R, et al. A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. Clin Pharmacokinet. 2012;51:681–93.View ArticlePubMedGoogle Scholar
  6. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012;69:1430–40.View ArticlePubMedGoogle Scholar
  7. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, et al. A γ-secretase inhibitor decreases amyloid-β production in the central nervous system. Ann Neurol. 2009;66:48–54.View ArticlePubMed CentralPubMedGoogle Scholar
  8. Barten DM, Meredith Jr JE, Zaczek R, Houston JG, Albright CF. γ-secretase inhibitors for Alzheimer’s disease: balancing efficacy and toxicity. Drugs R D. 2006;7:87–97.View ArticlePubMedGoogle Scholar
  9. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999;398:518–22.View ArticlePubMedGoogle Scholar
  10. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369:341–50.View ArticlePubMedGoogle Scholar
  11. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.View ArticlePubMedGoogle Scholar
  12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.View ArticlePubMedGoogle Scholar
  13. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983;17:37–49.
  14. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11:S13–21.
  15. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: Wiley; 1973.Google Scholar
  16. The R Project for Statistical Computing. http://www.r-project.org/. Accessed 30 Mar 2015.
  17. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008;65:1031–8.View ArticlePubMed CentralPubMedGoogle Scholar
  18. Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, Steinacker P, et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s disease. J Neural Transm. 2005;112:933–48.View ArticlePubMedGoogle Scholar
  19. Eli Lilly. Lilly halts development of semagacestat for Alzheimer’s disease based on preliminary results of phase III clinical trials: decision does not affect other Lilly Alzheimer’s compounds in development [17 Aug 2010 press release]. https://investor.lilly.com/releasedetail.cfm?releaseid=499794. Accessed 30 Mar 2015.
  20. Bristol-Myers Squibb. Statement on avagacestat development status [30 Nov 2012 press release]. http://www.bms.com/news/features/2012/Pages/AvagacestatDevelopmentStatus.aspx. Accessed 30 Mar 2015.
  21. Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase for the treatment of Alzheimer’s disease. J Pharmacol Exp Ther. 2009;331:598–608.View ArticlePubMedGoogle Scholar
  22. Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, et al. The mechanism of γ-secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261–74.View ArticlePubMed CentralPubMedGoogle Scholar

Copyright

© Doody et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement